Redirecting T lymphocyte specificity by T cell receptor gene transfer - A new era for immunotherapy

Molecular Aspects of Medicine

Volumn 28, Issue 1, 2007, Pages 115-142

  Engels, Boris ^a   Uckert, Wolfgang ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Gene transfer; Immunotherapy; Retroviral vector; T lymphocytes

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; ENVELOPE PROTEIN; GAG PROTEIN; GAMMA INTERFERON; HLA A2 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; PHYTOHEMAGGLUTININ; PLASMID DNA; POL PROTEIN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR PIT 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HELPER CELL; HUMAN; LYMPHOCYTE TRANSFER; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RETROVIRUS; REVIEW; T LYMPHOCYTE; TRANSGENE; VIRUS GENE;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4;

EID: 33847322059     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2006.12.006     Document Type: Review

References (149)

1. Aarnoudse C.A., Kruse M., Konopitzky R., Brouwenstijn N., and Schrier P.I. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning. Int. J. Cancer. 99 (2002) 7-13
2. Alajez N.M., Schmielau J., Alter M.D., Cascio M., and Finn O.J. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood 105 (2005) 4583-4589
3. Antony P.A., Piccirillo C.A., Akpinarli A., Finkelstein S.E., Speiss P.J., Surman D.R., Palmer D.C., Chan C.C., Klebanoff C.A., Overwijk W.W., Rosenberg S.A., and Restifo N.P. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174 (2005) 2591-2601
4. Arcaro A., Gregoire C., Boucheron N., Stotz S., Palmer E., Malissen B., and Luescher I.F. Essential role of CD8 palmitoylation in CD8 coreceptor function. J. Immunol. 165 (2000) 2068-2076
5. Berger C., Huang M.L., Gough M., Greenberg P.D., Riddell S.R., and Kiem H.P. Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J. Virol. 75 (2001) 799-808
6. Berger C., Blau C.A., Huang M.L., Iuliucci J.D., Dalgarno D.C., Gaschet J., Heimfeld S., Clackson T., and Riddell S.R. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 103 (2004) 1261-1269
7. Brentjens R.J., Latouche J.B., Santos E., Marti F., Gong M.C., Lyddane C., King P.D., Larson S., Weiss M., Riviere I., and Sadelain M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9 (2003) 279-286
8. Bunnell B.A., Muul L.M., Donahue R.E., Blaese R.M., and Morgan R.A. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 92 (1995) 7739-7743
9. Callender G.G., Rosen H.R., Roszkowski J.J., Lyons G.E., Li M., Moore T., Brasic N., McKee M.D., and Nishimura M.I. Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognition. Hepatology 43 (2006) 973-981
10. Calogero A., Hospers G.A., Kruse K.M., Schrier P.I., Mulder N.H., Hooijberg E., and de Leij L.F. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res. 20 (2000) 1793-1799
11. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Deist F.L., and Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
12. Chamoto K., Tsuji T., Funamoto H., Kosaka A., Matsuzaki J., Sato T., Abe H., Fujio K., Yamamoto K., Kitamura T., Takeshima T., Togashi Y., and Nishimura T. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res. 64 (2004) 386-390
13. Charo J., Finkelstein S.E., Grewal N., Restifo N.P., Robbins P.F., and Rosenberg S.A. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 65 (2005) 2001-2008
14. Check E. Gene therapy put on hold as third child develops cancer. Nature 433 (2005) 561
15. Cheng L., Du C., Murray D., Tong X., Zhang Y.A., Chen B.P., and Hawley R.G. A GFP reporter system to assess gene transfer and expression in human hematopoietic progenitor cells. Gene Ther. 4 (1997) 1013-1022
16. Clay T.M., Custer M.C., Sachs J., Hwu P., Rosenberg S.A., and Nishimura M.I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163 (1999) 507-513
17. Cohen C.J., Zheng Z., Bray R., Zhao Y., Sherman L.A., Rosenberg S.A., and Morgan R.A. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175 (2005) 5799-5808
18. Cohen C.J., Zhao Y., Zheng Z., Rosenberg S.A., and Morgan R.A. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66 (2006) 8878-8886
19. Cole D.J., Weil D.P., Shilyansky J., Custer M., Kawakami Y., Rosenberg S.A., and Nishimura M.I. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 55 (1995) 748-752
20. Cooper L.J., Kalos M., Lewinsohn D.A., Riddell S.R., and Greenberg P.D. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74 (2000) 8207-8212
21. Costello E., Munoz M., Buetti E., Meylan P.R., Diggelmann H., and Thali M. Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther. 7 (2000) 596-604
22. Dembic Z., Haas W., Weiss S., McCubrey J., Kiefer H., von Boehmer H., and Steinmetz M. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature 320 (1986) 232-238
23. Derbinski J., Schulte A., Kyewski B., and Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2 (2001) 1032-1039
24. Derby M., Alexander-Miller M., Tse R., and Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166 (2001) 1690-1697
25. Duarte R.F., Chen F.E., Lowdell M.W., Potter M.N., Lamana M.L., Prentice H.G., and Madrigal J.A. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy. Gene Ther. 9 (2002) 1359-1368
26. Dudley M.E., and Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 3 (2003) 666-675
27. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., and Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
28. Dudley M.E., Wunderlich J.R., Yang J.C., Sherry R.M., Topalian S.L., Restifo N.P., Royal R.E., Kammula U., White D.E., Mavroukakis S.A., Rogers L.J., Gracia G.J., Jones S.A., Mangiameli D.P., Pelletier M.M., Gea-Banacloche J., Robinson M.R., Berman D.M., Filie A.C., Abati A., and Rosenberg S.A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23 (2005) 2346-2357
29. Duval L., Schmidt H., Kaltoft K., Fode K., Jensen J.J., Sorensen S.M., Nishimura M.I., and von der Maase H. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin. Cancer Res. 12 (2006) 1229-1236
30. Emerman M., and Temin H.M. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 39 (1984) 449-467
31. Engels B., Cam H., Schuler T., Indraccolo S., Gladow M., Baum C., Blankenstein T., and Uckert W. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum. Gene Ther. 14 (2003) 1155-1168
32. Engels B., Noessner E., Frankenberger B., Blankenstein T., Schendel D.J., and Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum. Gene Ther. 16 (2005) 799-810
33. Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol. Immunother. 45 (1997) 131-136
34. Eshhar Z., Waks T., Gross G., and Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90 (1993) 720-724
35. Fehse B., Ayuk F.A., Kroger N., Fang L., Kuhlcke K., Heinzelmann M., Zabelina T., Fauser A.A., and Zander A.R. Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. Blood 104 (2004) 3408-3409
36. Frank O., Rudolph C., Heberlein C., von Neuhoff N., Schrock E., Schambach A., Schlegelberger B., Fehse B., Ostertag W., Stocking C., and Baum C. Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 104 (2004) 3543-3549
37. Gangadharan D., and Cheroutre H. The CD8 isoform CD8alphaalpha is not a functional homologue of the TCR co-receptor CD8alphabeta. Curr. Opin. Immunol. 16 (2004) 264-270
38. Ganss R., Ryschich E., Klar E., Arnold B., and Hammerling G.J. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62 (2002) 1462-1470
39. Gattinoni L., Klebanoff C.A., Palmer D.C., Wrzesinski C., Kerstann K., Yu Z., Finkelstein S.E., Theoret M.R., Rosenberg S.A., and Restifo N.P. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8(+) T cells. J. Clin. Invest. 115 (2005) 1616-1626
40. Gattinoni L., Finkelstein S.E., Klebanoff C.A., Antony P.A., Palmer D.C., Spiess P.J., Hwang L.N., Yu Z., Wrzesinski C., Heimann D.M., Surh C.D., Rosenberg S.A., and Restifo N.P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202 (2005) 907-912
41. Ghattas I.R., Sanes J.R., and Majors J.E. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol. Cell Biol. 11 (1991) 5848-5859
42. Gladow M., Becker C., Blankenstein T., and Uckert W. MLV-10A1 retrovirus pseudotype efficiently transduces primary human CD4+ T lymphocytes. J. Gene Med. 2 (2000) 409-415
43. Gladow M., Uckert W., and Blankenstein T. Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors. Eur. J. Immunol. 34 (2004) 1882-1891
44. Gotter J., Brors B., Hergenhahn M., and Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199 (2004) 155-166
45. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev. 157 (1997) 125-140
46. Greenberg P.D., Cheever M.A., and Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2-lymphocytes. J. Exp. Med. 154 (1981) 952-963
47. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., and Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
48. Hagani A.B., Riviere I., Tan C., Krause A., and Sadelain M. Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection. J. Gene Med. 1 (1999) 341-351
49. Hawley R.G., Lieu F.H., Fong A.Z., and Hawley T.S. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1 (1994) 136-138
50. Heemskerk M.H., Hoogeboom M., de Paus R.A., Kester M.G., van der Hoorn M.A., Goulmy E., Willemze R., and Falkenburg J.H. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102 (2003) 3530-3540
51. Heemskerk M.H., Hoogeboom M., Hagedoorn R., Kester M.G., Willemze R., and Falkenburg J.H. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J. Exp. Med. 199 (2004) 885-894
52. Heemskerk M.H., Hagedoorn R.S., van der Hoorn M.A., van der Veken L.T., Hoogeboom M., Kester M.G., Willemze R., and Falkenburg J.H. Efficiency of T cell receptor expression in dual specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood (2006) 10.1182/blood-2006-03-013318
53. Ho W.Y., Yee C., and Greenberg P.D. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J. Clin. Invest. 110 (2002) 1415-1417
54. Holler P.D., and Kranz D.M. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18 (2003) 255-264
55. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., and Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA 97 (2000) 5387-5392
56. Holst J., Vignali K.M., Burton A.R., and Vignali D.A. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat. Methods 3 (2006) 191-197
57. Hombach A., Heuser C., and Abken H. The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr. Gene Ther. 2 (2002) 211-226
58. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., Rimm A.A., Ringden O., Rozman C., Speck B., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
59. Hughes M.S., Yu Y.Y., Dudley M.E., Zheng Z., Robbins P.F., Li Y., Wunderlich J., Hawley R.G., Moayeri M., Rosenberg S.A., and Morgan R.A. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16 (2005) 457-472
60. Ivanov R., Hol S., Aarts T., Hagenbeek A., Slager E.H., and Ebeling S. UTY-specific TCR-transfer generates potential graft-versus-leukaemia effector T cells. Br. J. Haematol. 129 (2005) 392-402
61. Ivanov R., Hol S., Aarts T.I., Hagenbeek A., and Ebeling S.B. T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens. Clin. Exp. Immunol. 143 (2006) 78-84
62. Janssen E.M., Lemmens E.E., Wolfe T., Christen U., von Herrath M.G., and Schoenberger S.P. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 (2003) 852-856
63. Jung D., Jaeger E., Cayeux S., Blankenstein T., Hilmes C., Karbach J., Moebius U., Knuth A., Huber C., and Seliger B. Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. Hum. Gene Ther. 9 (1998) 53-62
64. Kavanaugh M.P., Miller D.G., Zhang W., Law W., Kozak S.L., Kabat D., and Miller A.D. Cell surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc. Natl. Acad. Sci. USA 91 (1994) 7071-7075
65. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., and Hammerling G.J. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol. 167 (2001) 5247-5253
66. Kessels H.W., Wolkers M.C., van den Boom M.D., van der Valk M.A., and Schumacher T.N. Immunotherapy through TCR gene transfer. Nat. Immunol. 2 (2001) 957-961
67. Kessels H.W., Schepers K., van den Boom M.D., Topham D.J., and Schumacher T.N. Generation of T cell help through a MHC class I-restricted TCR. J. Immunol. 177 (2006) 976-982
68. Khan N., Hislop A., Gudgeon N., Cobbold M., Khanna R., Nayak L., Rickinson A.B., and Moss P.A. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J. Immunol. 173 (2004) 7481-7489
69. Klebanoff C.A., Finkelstein S.E., Surman D.R., Lichtman M.K., Gattinoni L., Theoret M.R., Grewal N., Spiess P.J., Antony P.A., Palmer D.C., Tagaya Y., Rosenberg S.A., Waldmann T.A., and Restifo N.P. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. USA 101 (2004) 1969-1974
70. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., and Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76 (1990) 2462-2465
71. Korin Y.D., and Zack J.A. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J. Virol. 72 (1998) 3161-3168
72. Kuball J., Schmitz F.W., Voss R.H., Ferreira E.A., Engel R., Guillaume P., Strand S., Romero P., Huber C., Sherman L.A., and Theobald M. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A21-specific TCR. Immunity 22 (2005) 117-129
73. Kurokawa M., Tong J., Matsui T., Masuko-Hongo K., Yabe T., Nishioka K., Yamamoto K., and Kato T. Paired cloning of the T cell receptor alpha and beta genes from a single T cell without the establishment of a T cell clone. Clin. Exp. Immunol. 123 (2001) 340-345
74. Labrecque N., Whitfield L.S., Obst R., Waltzinger C., Benoist C., and Mathis D. How much TCR does a T cell need?. Immunity 15 (2001) 71-82
75. Lam J.S., Reeves M.E., Cowherd R., Rosenberg S.A., and Hwu P. Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. Hum. Gene Ther. 7 (1996) 1415-1422
76. Li Z., Dullmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., Forster M., Stocking C., Wahlers A., Frank O., Ostertag W., Kuhlcke K., Eckert H.G., Fehse B., and Baum C. Murine leukemia induced by retroviral gene marking. Science 296 (2002) 497
77. Luznik L., Jalla S., Engstrom L.W., Iannone R., and Fuchs E.J. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98 (2001) 3456-3464
78. Lyons G.E., Roszkowski J.J., Man S., Yee C., Kast W.M., and Nishimura M.I. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol. Immunother. 55 (2006) 1142-1150
79. May Jr. K.F., Chen L., Zheng P., and Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 62 (2002) 3459-3465
80. Melief C.J., and Kast W.M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145 (1995) 167-177
81. Miller A.D., and Chen F. Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J. Virol. 70 (1996) 5564-5571
82. Miller D.G., and Miller A.D. A family of retroviruses that utilize related phosphate transporters for cell entry. J. Virol. 68 (1994) 8270-8276
83. Mommaas B., van Halteren A.G., Pool J., van der Veken L., Wieles B., Heemskerk M.H., and Goulmy E. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica 90 (2005) 1415-1421
84. Morgan R.A., Dudley M.E., Yu Y.Y., Zheng Z., Robbins P.F., Theoret M.R., Wunderlich J.R., Hughes M.S., Restifo N.P., and Rosenberg S.A. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171 (2003) 3287-3295
85. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., Royal R.E., Topalian S.L., Kammula U.S., Restifo N.P., Zheng Z., Nahvi A., de Vries C.R., Rogers-Freezer L.J., Mavroukakis S.A., and Rosenberg S.A. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
86. Morris E.C., Tsallios A., Bendle G.M., Xue S.A., and Stauss H.J. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. USA 102 (2005) 7934-7939
87. Muhlebach M.D., Schmitt I., Steidl S., Stitz J., Schweizer M., Blankenstein T., Cichutek K., and Uckert W. Transduction efficiency of MLV but not of HIV-1 vectors is pseudotype dependent on human primary T lymphocytes. J. Mol. Med. 81 (2003) 801-810
88. Onodera M., Nelson D.M., Yachie A., Jagadeesh G.J., Bunnell B.A., Morgan R.A., and Blaese R.M. Development of improved adenosine deaminase retroviral vectors. J. Virol. 72 (1998) 1769-1774
89. Orentas R.J., Roskopf S.J., Nolan G.P., and Nishimura M.I. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin. Immunol. 98 (2001) 220-228
90. Overwijk W.W., Theoret M.R., Finkelstein S.E., Surman D.R., de Jong L.A., Vyth-Dreese F.A., Dellemijn T.A., Antony P.A., Spiess P.J., Palmer D.C., Heimann D.M., Klebanoff C.A., Yu Z., Hwang L.N., Feigenbaum L., Kruisbeek A.M., Rosenberg S.A., and Restifo N.P. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198 (2003) 569-580
91. Pardoll D.M., and Topalian S.L. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10 (1998) 588-594
92. Pogulis R.J., and Pease L.R. A retroviral vector that directs simultaneous expression of alpha and beta T cell receptor genes. Hum. Gene Ther. 9 (1998) 2299-2304
93. Pollok K.E., Hanenberg H., Noblitt T.W., Schroeder W.L., Kato I., Emanuel D., and Williams D.A. High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J. Virol. 72 (1998) 4882-4892
94. Pollok K.E., van der Loo J.C., Cooper R.J., Kennedy L., and Williams D.A. Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. Hum. Gene Ther. 10 (1999) 2221-2236
95. Porter C.D., Collins M.K., Tailor C.S., Parkar M.H., Cosset F.L., Weiss R.A., and Takeuchi Y. Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors. Hum. Gene Ther. 7 (1996) 913-919
96. Rapoport A.P., Stadtmauer E.A., Aqui N., Badros A., Cotte J., Chrisley L., Veloso E., Zheng Z., Westphal S., Mair R., Chi N., Ratterree B., Pochran M.F., Natt S., Hinkle J., Sickles C., Sohal A., Ruehle K., Lynch C., Zhang L., Porter D.L., Luger S., Guo C., Fang H.B., Blackwelder W., Hankey K., Mann D., Edelman R., Frasch C., Levine B.L., Cross A., and June C.H. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11 (2005) 1230-1237
97. Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E.K., Camphausen K., Luiten R.M., de Ru A.H., Neijssen J., Griekspoor A., Mesman E., Verreck F.A., Spits H., Schlom J., van Veelen P., and Neefjes J.J. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203 (2006) 1259-1271
98. Riddell S.R., Elliott M., Lewinsohn D.A., Gilbert M.J., Wilson L., Manley S.A., Lupton S.D., Overell R.W., Reynolds T.C., Corey L., and Greenberg P.D. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2 (1996) 216-223
99. Rooney C.M., Smith C.A., Ng C.Y., Loftin S., Li C., Krance R.A., Brenner M.K., and Heslop H.E. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345 (1995) 9-13
100. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., and White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86 (1994) 1159-1166
101. Roszkowski J.J., Yu D.C., Rubinstein M.P., McKee M.D., Cole D.J., and Nishimura M.I. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J. Immunol. 170 (2003) 2582-2589
102. Roszkowski J.J., Lyons G.E., Kast W.M., Yee C., Van Besien K., and Nishimura M.I. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 65 (2005) 1570-1576
103. Sadelain M., Riviere I., and Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer. 3 (2003) 35-45
104. Sadovnikova E., and Stauss H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci USA 93 (1996) 13114-13118
105. Salter R.D., Benjamin R.J., Wesley P.K., Buxton S.E., Garrett T.P., Clayberger C., Krensky A.M., Norment A.M., Littman D.R., and Parham P. A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2. Nature 345 (1990) 41-46
106. Schaft N., Willemsen R.A., de Vries J., Lankiewicz B., Essers B.W., Gratama J.W., Figdor C.G., Bolhuis R.L., Debets R., and Adema G.J. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J. Immunol. 170 (2003) 2186-2194
107. Schambach A., Wodrich H., Hildinger M., Bohne J., Krausslich H.G., and Baum C. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol. Ther. 2 (2000) 435-445
108. Scholten K.B., Schreurs M.W., Ruizendaal J.J., Kueter E.W., Kramer D., Veenbergen S., Meijer C.J., and Hooijberg E. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin. Immunol. 114 (2005) 119-129
109. Scholten K.B., Kramer D., Kueter E.W., Graf M., Schoedl T., Meijer C.J., Schreurs M.W., and Hooijberg E. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 119 (2006) 135-145
110. Schreiber H. Tumor immunology. In: Paul W.E. (Ed). Fundamental Immunology (2003), Lippincott Williams and Wilkins, Philadelphia, PA 1557-1592
111. Seitz S., Schneider C.K., Malotka J., Nong X., Engel A.G., Wekerle H., Hohlfeld R., and Dornmair K. Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues. Proc. Natl. Acad. Sci. USA 103 (2006) 12057-12062
112. Shedlock D.J., and Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300 (2003) 337-339
113. Sommermeyer D., Neudorfer J., Weinhold M., Leisegang M., Engels B., Noessner E., Heemskerk M.H., Charo J., Schendel D.J., Blankenstein T., Bernhard H., and Uckert W. Designer T cells by T cell receptor replacement. Eur. J. Immunol. 36 (2006) 3052-3059
114. Stanislawski T., Voss R.H., Lotz C., Sadovnikova E., Willemsen R.A., Kuball J., Ruppert T., Bolhuis R.L., Melief C.J., Huber C., Stauss H.J., and Theobald M. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2 (2001) 962-970
115. Straathof K.C., Pule M.A., Yotnda P., Dotti G., Vanin E.F., Brenner M.K., Heslop H.E., Spencer D.M., and Rooney C.M. An inducible caspase 9 safety switch for T-cell therapy. Blood 105 (2005) 4247-4254
116. Stripecke R., Carmen Villacres M., Skelton D., Satake N., Halene S., and Kohn D. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 6 (1999) 1305-1312
117. Strom T.S., Gabbard W., Kelly P.F., Cunningham J.M., and Nienhuis A.W. Functional correction of T cells derived from patients with the Wiskott-Aldrich syndrome (WAS) by transduction with an oncoretroviral vector encoding the WAS protein. Gene Ther. 10 (2003) 803-809
118. Sun J.C., Williams M.A., and Bevan M.J. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. 5 (2004) 927-933
119. Surman D.R., Dudley M.E., Overwijk W.W., and Restifo N.P. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J. Immunol. 164 (2000) 562-565
120. Tahara H., Fujio K., Araki Y., Setoguchi K., Misaki Y., Kitamura T., and Yamamoto K. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte. J. Immunol. 171 (2003) 2154-2160
121. Tey S.K., Bollard C.M., and Heslop H.E. Adoptive T-cell transfer in cancer immunotherapy. Immunol. Cell Biol. 84 (2006) 281-289
122. Tsuji T., Yasukawa M., Matsuzaki J., Ohkuri T., Chamoto K., Wakita D., Azuma T., Niiya H., Miyoshi H., Kuzushima K., Oka Y., Sugiyama H., Ikeda H., and Nishimura T. Generation of human tumor-specific, HLA class I-restricted Th1 and Tc1 cells by cell engineering with tumor peptide-specific T cell receptor genes. Blood (2005)
123. Tuma R.A., Giannino R., Guirnalda P., Leiner I., and Pamer E.G. Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus. J. Clin. Invest. 110 (2002) 1493-1501
124. Uckert W., Willimsky G., Pedersen F.S., Blankenstein T., and Pedersen L. RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes. Hum. Gene Ther. 9 (1998) 2619-2627
125. Uckert W., Becker C., Gladow M., Klein D., Kammertoens T., Pedersen L., and Blankenstein T. Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype. Hum. Gene Ther. 11 (2000) 1005-1014
126. Ueno T., Fujiwara M., Tomiyama H., Onodera M., and Takiguchi M. Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes. Eur. J. Immunol. 34 (2004) 3379-3388
127. Unutmaz D., KewalRamani V.N., Marmon S., and Littman D.R. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189 (1999) 1735-1746
128. van der Veken L.T., Hoogeboom M., de Paus R.A., Willemze R., Falkenburg J.H., and Heemskerk M.H. HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity. Gene Ther. 12 (2005) 1686-1695
129. van der Veken L.T., Hagedoorn R.S., van Loenen M.M., Willemze R., Falkenburg J.H., and Heemskerk M.H. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity. Cancer Res. 66 (2006) 3331-3337
130. Veillette A., Bookman M.A., Horak E.M., and Bolen J.B. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell 55 (1988) 301-308
131. Verhoeyen E., Dardalhon V., Ducrey-Rundquist O., Trono D., Taylor N., and Cosset F.L. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 101 (2003) 2167-2174
132. Voss R.H., Kuball J., and Theobald M. Designing TCR for cancer immunotherapy. Methods Mol Med. 109 (2005) 229-256
133. Voss R.H., Kuball J., Engel R., Guillaume P., Romero P., Huber C., and Theobald M. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol. Res. 34 (2006) 67-87
134. Walker R.E., Bechtel C.M., Natarajan V., Baseler M., Hege K.M., Metcalf J.A., Stevens R., Hazen A., Blaese R.M., Chen C.C., Leitman S.F., Palensky J., Wittes J., Davey Jr. R.T., Falloon J., Polis M.A., Kovacs J.A., Broad D.F., Levine B.L., Roberts M.R., Masur H., and Lane H.C. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96 (2000) 467-474
135. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., and Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333 (1995) 1038-1044
136. Willemsen R.A., Weijtens M.E., Ronteltap C., Eshhar Z., Gratama J.W., Chames P., and Bolhuis R.L. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 7 (2000) 1369-1377
137. Willemsen R., Ronteltap C., Heuveling M., Debets R., and Bolhuis R. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha. Gene Ther. 12 (2005) 140-146
138. Willemsen R.A., Sebestyen Z., Ronteltap C., Berrevoets C., Drexhage J., and Debets R. CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10. J. Immunol. 177 (2006) 991-998
139. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., and Sissons J.G. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J. Virol. 70 (1996) 7569-7579
140. Woods N.B., Bottero V., Schmidt M., von Kalle C., and Verma I.M. Gene therapy: therapeutic gene causing lymphoma. Nature 440 (2006) 1123
141. Xue S.A., Gao L., Hart D., Gillmore R., Qasim W., Thrasher A., Apperley J., Engels B., Uckert W., Morris E., and Stauss H. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106 (2005) 3062-3067
142. Yang L., and Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 102 (2005) 4518-4523
143. Yang L., Qin X.F., Baltimore D., and Van Parijs L. Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc. Natl. Acad. Sci. USA 99 (2002) 6204-6209
144. Yee C., Thompson J.A., Roche P., Byrd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., and Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192 (2000) 1637-1644
145. Yee C., Thompson J.A., Byrd D., Riddell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99 (2002) 16168-16173
146. Zeh III H.J., Perry-Lalley D., Dudley M.E., Rosenberg S.A., and Yang J.C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162 (1999) 989-994
147. Zhao Y., Zheng Z., Robbins P.F., Khong H.T., Rosenberg S.A., and Morgan R.A. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174 (2005) 4415-4423
148. Zhao Y., Zheng Z., Khong H.T., Rosenberg S.A., and Morgan R.A. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. J. Immunother. 29 (2006) 398-406
149. Zhou X., Cui Y., Huang X., Yu Z., Thomas A.M., Ye Z., Pardoll D.M., Jaffee E.M., and Cheng L. Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum. Gene Ther. 14 (2003) 1089-1105